{"filing":{"accession_number":"0001193125-26-381912","cik":"0002056611","ticker":null,"company_name":"Latigo Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"ltgo-20260903.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-20260903.htm"},"events":[{"id":31622,"run_id":29027,"accession_number":"0001193125-26-381912","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on September 3, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), including condensed balance sheets and statements of operations showing R\u0026D expenses of $21.2M, G\u0026A expenses of $4.6M, and a net loss of $25.8M. The press release is attached as Exhibit 99.1 and incorporates financial results alongside recent business highlights including the completed IPO and clinical trial progress.","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34555,"accession_number":"0001193125-26-381912","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on September 3, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), including condensed balance sheets and statements of operations showing R\u0026D expenses of $21.2M, G\u0026A expenses of $4.6M, and a net loss of $25.8M. The press release is attached as Exhibit 99.1 and incorporates financial results alongside recent business highlights including the completed IPO and clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:07.388167+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34555,"accession_number":"0001193125-26-381912","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on September 3, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), including condensed balance sheets and statements of operations showing R\u0026D expenses of $21.2M, G\u0026A expenses of $4.6M, and a net loss of $25.8M. The press release is attached as Exhibit 99.1 and incorporates financial results alongside recent business highlights including the completed IPO and clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:35:07.388167+00:00","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-09-03"}]}